Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Multiple Doses of AT-527 in Healthy Subjects
NCT04711187Phase 1Completed
- Sponsor
- Atea Pharmaceuticals
- Start
- Nov 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bemnifosbuvir in coronavirus disease 2019 (COVID-19) and hepatitis C (HCV) (7 arms), sponsored by Atea Pharmaceuticals. Primary endpoint: Proportions of subjects experiencing treatment-emergent adverse events at Day 10. Started Nov 2020; status: completed.
02
Drugs
bemnifosbuvir
03
Conditions
coronavirus disease 2019 (COVID-19)hepatitis C (HCV)
Beyond the preview
Go deeper on NCT04711187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04711187.